Skip to Content
Merck
CN
  • Retinal vascular occlusion after vitrectomy with retrobulbar anesthesia-observational case series and survey of literature.

Retinal vascular occlusion after vitrectomy with retrobulbar anesthesia-observational case series and survey of literature.

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie (2011-08-19)
Christoph Tappeiner, Justus G Garweg
ABSTRACT

Severe postoperative loss of vision has been occasionally reported as a rare complication of retrobulbar anesthesia, and several possible causes have been proposed in the literature. In this work, our own and other investigators' experiences with these complications are surveyed with a view to identifying its pathophysiology. This observational case series refers to six patients who presented during a 3-month period with occlusion of either the central artery itself (n = 3) or a branch thereof (n = 3) 2-14 days after uneventful vitreoretinal surgery following retrobulbar anesthesia with a commercial preparation of mepivacaine (1% Scandicain®, Astra Chemicals, Sweden) containing methyl- and propyl parahydroxybenzoate as preservatives. Three of the patients carried risk factors, which were medically controlled. In three individuals, vasoocclusion was observed after a second vitreoretinal intervention, which was performed 3-12 months after uneventful primary surgery. Good visual recovery was observed in only one instance. In patients who were anesthetized with preservative-free mepivacaine, no vasoocclusion occurred. In individuals who were anesthetized with mepivacaine containing the preservatives methyl- and propyl parahydroxybenzoate, a tenfold increase in the incidence of eyes requiring re-operation was documented, with a 2- to 14-day lapse in the onset of vasoocclusion. These findings reveal a possible implication of preservatives contained in the local anesthetic solution for the vasoocclusive events. Due to this potential hazard, the use of preservative-free preparations of local anesthesia in ocular surgery is emphasized in order to prevent this sight-threatening complication.

MATERIALS
Product Number
Brand
Product Description

Propyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
Supelco
Propylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Methyl Paraben, PESTANAL®, analytical standard
Methyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Propyl 4-hydroxybenzoate, ≥99%
Sigma-Aldrich
Propyl 4-hydroxybenzoate, BioXtra
Sigma-Aldrich
Propyl 4-hydroxybenzoate, tested according to Ph. Eur.
Sigma-Aldrich
Methyl 4-hydroxybenzoate, tested according to Ph. Eur.
Sigma-Aldrich
Methyl 4-hydroxybenzoate, BioReagent, suitable for insect cell culture
Sigma-Aldrich
Methyl 4-hydroxybenzoate, ReagentPlus®, ≥99.0%, crystalline
Sigma-Aldrich
Methyl 4-hydroxybenzoate, analytical standard
Sigma-Aldrich
Methyl 4-hydroxybenzoate, ≥99%, FCC
Sigma-Aldrich
Methyl 4-hydroxybenzoate, BioXtra, ≥99.0% (titration)